Author:
Wang Lingzhi,Chong Wan Qin,Ong Pei Shi,Goh Boon Cher
Publisher
Springer International Publishing
Reference14 articles.
1. Urien S, Barré J, Morin C, et al. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Investig New Drugs. 1996;14(2):147–51.
2. Bruno R, Olivares R, Berille J, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res. 2003;9(3):1077–82.
3. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20(17):3683–90.
4. Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clin Pharmacokinet. 2018;57(1):7–19.
5. Fujita K, Sasaki Y. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the ‘real world’. Drug Metab Pharmacokinet. 2014;29(1):20–8.